MDG1.DE
Price:
$0.1335
Market Cap:
$1.97M
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immun...[Read more]
Industry
Biotechnology
IPO Date
2000-06-30
Stock Exchange
XETRA
Ticker
MDG1.DE
According to Medigene AG’s latest financial reports and current stock price. The company's current ROE is -58.49%. This represents a change of 190.90% compared to the average of -20.11% of the last 4 quarters.
The mean historical ROE of Medigene AG over the last ten years is -27.02%. The current -58.49% ROE has changed 116.50% with respect to the historical average. Over the past ten years (40 quarters), MDG1.DE's ROE was at its highest in in the March 2022 quarter at 15.53%. The ROE was at its lowest in in the December 2020 quarter at -30.74%.
Average
-27.02%
Median
-19.07%
Minimum
-76.79%
Maximum
-11.73%
Discovering the peaks and valleys of Medigene AG ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 241.34%
Maximum Annual ROE = -11.73%
Minimum Annual Increase = -59.00%
Minimum Annual ROE = -76.79%
Year | ROE | Change |
---|---|---|
2023 | -76.79% | 241.34% |
2022 | -22.50% | 0.99% |
2021 | -22.28% | -59.00% |
2020 | -54.32% | 122.67% |
2019 | -24.40% | 53.72% |
2018 | -15.87% | 0.75% |
2017 | -15.75% | 30.42% |
2016 | -12.08% | -16.39% |
2015 | -14.45% | 23.13% |
2014 | -11.73% | -58.61% |
The current ROE of Medigene AG (MDG1.DE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-40.52%
5-year avg
-40.06%
10-year avg
-27.02%
Medigene AG’s ROE is greater than Evotec SE (-21.53%), greater than MorphoSys AG (-183.80%), greater than Paion AG (-8.51%), greater than Biofrontera AG (-216.00%), less than Aixtron Se (12.39%),
Company | ROE | Market cap |
---|---|---|
-21.53% | $1.32B | |
-183.80% | $2.53B | |
-8.51% | $2.71M | |
-216.00% | $20.67M | |
12.39% | $1.84B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Medigene AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Medigene AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Medigene AG's ROE?
How is the ROE calculated for Medigene AG (MDG1.DE)?
What is the highest ROE for Medigene AG (MDG1.DE)?
What is the 3-year average ROE for Medigene AG (MDG1.DE)?
What is the 5-year average ROE for Medigene AG (MDG1.DE)?
How does the current ROE for Medigene AG (MDG1.DE) compare to its historical average?